Cancer survival: an overview of measures, uses, and interpretation.

Survival statistics are of great interest to patients, clinicians, researchers, and policy makers. Although seemingly simple, survival can be confusing: there are many different survival measures with a plethora of names and statistical methods developed to answer different questions. This paper aims to describe and disseminate different survival measures and their interpretation in less technical language. In addition, we introduce templates to summarize cancer survival statistic organized by their specific purpose: research and policy versus prognosis and clinical decision making.

[1]  A. Mariotto,et al.  Improved estimates of cancer-specific survival rates from population-based data. , 2010, Journal of the National Cancer Institute.

[2]  S. Altekruse,et al.  Racial and ethnic disparities in cancer survival by neighborhood socioeconomic status in Surveillance, Epidemiology, and End Results (SEER) Registries. , 2014, Journal of the National Cancer Institute. Monographs.

[3]  H. Weir,et al.  The effect of multiple primary rules on population-based cancer survival , 2013, Cancer Causes & Control.

[4]  G. McLachlan,et al.  Analysing Survival Data from Clinical Trials and Observational Studies; E. Marubini & M. G. Valsecchi Published by John Wiley & Sons 414 pages ISBN 0-971-93987-0. , 1995, British journal of clinical pharmacology.

[5]  H. Brenner,et al.  Up-to-date and precise estimates of cancer patient survival: model-based period analysis. , 2006, American journal of epidemiology.

[6]  P C Lambert,et al.  Should relative survival be used with lung cancer data? , 2012, British Journal of Cancer.

[7]  E. Feuer,et al.  SEER Cancer Statistics Review, 1975-2003 , 2006 .

[8]  Binbing Yu,et al.  SELECTING THE NUMBER OF CHANGE-POINTS IN SEGMENTED LINE REGRESSION. , 2009, Statistica Sinica.

[9]  Estimates of long‐term survival for newly diagnosed cancer patients , 2006, Cancer.

[10]  T. Hakulinen.  On long-term relative survival rates. , 1977, Journal of chronic diseases.

[11]  John D. Kalbfleisch,et al.  The Statistical Analysis of Failure Data , 1986, IEEE Transactions on Reliability.

[12]  Coraline Danieli,et al.  Cancer net survival on registry data: Use of the new unbiased Pohar‐Perme estimator and magnitude of the bias with the classical methods , 2013, International journal of cancer.

[13]  E. Feuer,et al.  The Surveillance, Epidemiology, and End Results Cancer Survival Calculator SEER*CSC: validation in a managed care setting. , 2014, Journal of the National Cancer Institute. Monographs.

[14]  Eric J Feuer,et al.  Life tables adjusted for comorbidity more accurately estimate noncancer survival for recently diagnosed cancer patients. , 2013, Journal of clinical epidemiology.

[15]  Bernard Rachet,et al.  Cancer survival in five continents: a worldwide population-based study (CONCORD). , 2008, The Lancet. Oncology.

[16]  E. Feuer,et al.  Cumulative cause-specific mortality for cancer patients in the presence of other causes: a crude analogue of relative survival. , 2000, Statistics in medicine.

[17]  R. Tiwari,et al.  Modelling population‐based cancer survival trends by using join point models for grouped survival data , 2009, Journal of the Royal Statistical Society. Series A,.

[18]  T. Hakulinen,et al.  Choosing the net survival method for cancer survival estimation. , 2015, European Journal of Cancer.

[19]  J. Kalbfleisch,et al.  The Statistical Analysis of Failure Time Data , 1980 .

[20]  E. Feuer,et al.  Current estimates of the cure fraction: a feasibility study of statistical cure for breast and colorectal cancer. , 2014, Journal of the National Cancer Institute. Monographs.

[21]  T. Hakulinen,et al.  Cancer survival corrected for heterogeneity in patient withdrawal. , 1982, Biometrics.

[22]  Steven Woloshin,et al.  Providing clinicians and patients with actual prognosis: cancer in the context of competing causes of death. , 2014, Journal of the National Cancer Institute. Monographs.

[23]  P. Prorok,et al.  Evidence of a healthy volunteer effect in the prostate, lung, colorectal, and ovarian cancer screening trial. , 2007, American journal of epidemiology.

[24]  E. Feuer,et al.  Health-care utilization by prognosis profile in a managed care setting: using the Surveillance, Epidemiology and End Results Cancer Survival Calculator SEER*CSC. , 2014, Journal of the National Cancer Institute. Monographs.

[25]  Steven Woloshin,et al.  When do changes in cancer survival mean progress? The insight from population incidence and mortality. , 2014, Journal of the National Cancer Institute. Monographs.

[26]  P. Lambert,et al.  Estimating net survival in population‐based cancer studies , 2013, International journal of cancer.

[27]  Janez Stare,et al.  On Estimation in Relative Survival , 2012, Biometrics.

[28]  James F. Watkins,et al.  Analysing Survival Data from Clinical Trials and Observational Studies. , 1995 .

[29]  A. Mariotto,et al.  Evaluation of North American Association of Central Cancer Registries' (NAACCR) data for use in population-based cancer survival studies. , 2014, Journal of the National Cancer Institute. Monographs.

[30]  E. Feuer,et al.  The Cancer Survival Query System: Making survival estimates from the Surveillance, Epidemiology, and End Results program more timely and relevant for recently diagnosed patients , 2012, Cancer.

[31]  Mike Quinn,et al.  Standard cancer patient population for age standardising survival ratios. , 2004, European journal of cancer.

[32]  D. R. Lewis,et al.  Adolescent and young adult cancer survival. , 2014, Journal of the National Cancer Institute. Monographs.

[33]  S. Altekruse,et al.  The impact of follow-up type and missed deaths on population-based cancer survival studies for Hispanics and Asians. , 2014, Journal of the National Cancer Institute. Monographs.

[34]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.

[35]  F. Ederer,et al.  The relative survival rate: a statistical methodology. , 1961, National Cancer Institute monograph.

[36]  A Morabito,et al.  Prognostic factors and risk groups: some results given by using an algorithm suitable for censored survival data. , 1983, Statistics in medicine.

[37]  J. Klein,et al.  Survival Analysis: Techniques for Censored and Truncated Data , 1997 .

[38]  A. Mariotto,et al.  The impact of state-specific life tables on relative survival. , 2014, Journal of the National Cancer Institute. Monographs.